Natco to partner Lupin to market generic breast cancer drug
Hyderabad-based Natco Pharma has filed an abbreviated new drug application with US Food and Drugs Administration for a generic version of Lapatinib Ditosylate tablets of 250 mg strength, used for the treatment of breast cancer. Natco said it has partnered with Lupin to market the product.
June 23, 2011 / 14:11 IST
Moneycontrol Bureau
Hyderabad-based Natco Pharma has filed an abbreviated new drug application with US Food and Drugs Administration for a generic version of Lapatinib Ditosylate tablets of 250 mg strength, used for the treatment of breast cancer. Natco said it has partnered with Lupin to market the product.Natco
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
